*From the Authors*:

We appreciate Mahler's correspondence related to our research statement ([@bib1]), the goal of which was to identify knowledge gaps that future research studies can address to efficiently translate biomarkers into clinical practice. To reach this goal, we chose to focus on example biomarkers for select lung diseases rather than create a comprehensive list of all biomarkers for all pulmonary diseases. As stated in the article, "the biomarkers discussed in this research statement are not intended to be comprehensive." Thus, we did not state or intend to imply that fibrinogen is the "sole" biomarker in chronic obstructive pulmonary disease (COPD). We agree with Mahler that the peak inspiratory flow rate is a promising COPD biomarker, and encourage studies of this and other promising biomarkers for COPD and other lung diseases.
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